Alpha-1 antitrypsin (AAT) deficiency - What are the treatment options?

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 16, 2009, Pages 2653-2661

  Modrykamien, Ariel ^a   Stoller, James K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alpha 1 antitrypsin deficiency; Augmentation therapy; Chronic obstructive pulmonary disease; Emphysema; Neutrophil elastase

Indexed keywords

ALPHA 1 ANTITRYPSIN; BRONCHODILATING AGENT; LEUKOCYTE ELASTASE INHIBITOR; PARVOVIRUS VECTOR; PLACEBO; RESPITIN; SMALL INTERFERING RNA; STEROID; TRYPSONE; UNCLASSIFIED DRUG; ZEMAIRA;

AEROSOL; ALPHA 1 ANTITRYPSIN DEFICIENCY; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENE SILENCING; HUMAN; LIVER DISEASE; LUNG EMPHYSEMA; LUNG FUNCTION; NAUSEA; NONHUMAN; OXYGEN THERAPY; REVIEW; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ALPHA 1-ANTITRYPSIN DEFICIENCY; HUMANS;

EID: 72949101418     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903300111     Document Type: Review

References (51)

1. Wood AM, Stockley RA. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007;74:481-492
2. Ranes J, Stoller JK. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med 2005;26:154-166
3. Laurell CB, Eriksson S. [Hypo-Alpha-1 Antitrypsinemia.]. Verh Dtsch Ges Inn Med 1964;70:537-539
4. Laurell CB, Eriksson S. The serum alpha-1 antitrypsin in families with hypo-Alpha-L-antitrypsinemia. Clin Chim Acta 1965;11:395-398
5. Carrell RW. What we owe to alpha-(1) antitrypsin and to Carl-Bertil Laurell. COPD 2004;1:71-84
6. Sveger T. Liver disease in alpha-1 antitrypsin deficiency detected by screening of 200,0 infants. N Engl J Med 1976;294:1316-1321
7. O'Brien ML, Buist NR, Murphey WH. Neonatal screening for alpha-1 antitrypsin deficiency. J Pediatr 1978;92:1006-1010
8. Silverman EK, Miletich JP, Pierce JA, et al. Alpha-1 antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989;140:961-966
9. Spence WC, Morris JE, Pass K, Murphy PD. Molecular confirmation of alpha-1 antitrypsin genotypes in newborn dried blood specimens. Biochem Med Metab Biol 1993;50:233-240
10. DeMeo DL, Silverman EK. Alpha-1 antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259-264
11. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1 antitrypsin deficiency. Am J Med 1988;84:13-31
12. Stoller JK, Aboussouan LS. Alpha-1 antitrypsin deficiency. Lancet 2005;365:2225-2236
13. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-2073
14. Tutic M, Bloch KE, Lardinois D, et al. Long-term results after lung volume reduction surgery in patients with alpha-1 antitrypsin deficiency. J Thorac Cardiovasc Surg 2004;128:408-413
15. Stoller JK, Gildea TR, Ries AL, et al. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg 2007;83:241-251
16. Stoller JK. Clinical features and natural history of severe alpha-1 antitrypsin deficiency. Roger S. Mitchell Lecture. Chest 1997;111:123S-8S
17. Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1 antitrypsin deficiency. Am J Med 1988;84:52-62
18. Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha-1 antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981;68:1158-1165
19. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha-1 antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316:1055-1062
20. Kolarich D, Turecek PL, Weber A, et al. Biochemical, molecular characterization, and glycoproteomic analyses of alpha-(1) proteinase inhibitor products used for replacement therapy. Transfusion 2006;46:1959-1977
21. Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha-1 antitrypsin deficiency. Jama 1988;260:1259-1264
22. Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha-1 antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997;112:607-613
23. Piitulainen E, Bernspang E, Bjorkman S, Berntorp E. Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha-(1) antitrypsin. Eur J Clin Pharmacol 2003;59:151-156
24. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha-(1) antitrypsin, Respitin. Chest 2002;122:66-74
25. Heresi GA, Stoller JK. Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2008;8:515-526
26. Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha-1 proteinase inhibitor, Zemaira. Copd 2006;3:17-23
27. Seersholm N, Wencker M, Banik N, et al. Does alpha-1 antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha-1 AT study group. Eur Respir J 1997;10:2260-2263
28. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha-1 antitrypsin. Am J Respir Crit Care Med 1998;158:49-59
29. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha-(1) antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468-1472
30. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J 2009;33:1345-1353
31. Gottlieb DJ, Luisetti M, Stone PJ, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha-(1) antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med 2000;162:2069-2072
32. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000;118:1480-1485
33. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha-(1) protease inhibitor deficiency before and during therapy with IV alpha-(1) protease inhibitor. Chest 2001;119:737-744
34. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2002;165:1494-1498
35. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-819
36. Dawkins PA, Dawkins CL, Wood AM, et al. Rate of progression of lung function impairment in alpha-1 antitrypsin deficiency. Eur Respir J 2009;33:1338-1344
37. Piliang MP, Stoller JK. Women with ulcerating, painful skin lesions. Cleve Clin J Med 2008;75:414, 418, 422
38. Wencker M, Banik N, Buhl R, et al. [Long-term therapy of alpha-1 antitrypsin-deficiency-associated pulmonary emphysema with human alpha-1 antitrypsin]. Pneumologie 1998;52:545-552 (Pubitemid 28495207)
39. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha-1 antitrypsin: patterns of use and adverse events. Chest 2003;123:1425-1434
40. Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha-1 antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004;15:93-128
41. Song S, Morgan M, Ellis T, et al. Sustained secretion of human alpha-1 antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998;95:14384-14388
42. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha-l antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17:1177-1186
43. Parfrey H, Dafforn TR, Belorgey D, et al. Inhibiting polymerization: new therapeutic strategies for Z alpha-1 antitrypsin-related emphysema. Am J Respir Cell Mol Biol 2004;31:133-139
44. Cruz PE, Mueller C, Cossette TL, et al. In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest 2007;87:893-902
45. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha-1 antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000;97:1796-1801
46. Cantin AM, Woods DE, Cloutier D, et al. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha-1 proteinase inhibitor. Am J Respir Cell Mol Biol 2002;27:659-665
47. McNab GL, Ahmad A, Mistry D, Stockley RA. Modification of gene expression and increase in alpha-1 antitrypsin (alpha1 AT) secretion after homologous recombination in alpha1-AT-deficient monocytes. Hum Gene Ther 2007;18:1171-1177
48. Hubbard RC, Casolaro MA, Mitchell M, et al. Fate of aerosolized recombinant DNA-produced alpha-1 antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci USA 1989;86:680-684
49. Spencer LT, Humphries JE, Brantly ML. Antibody response to aerosolized transgenic human alpha-1 antitrypsin. N Engl J Med 2005;352:2030-2031
50. Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;167:1387-1392
51. Sandhaus RA, Turino G, Stocks J, et al. Alpha-1 antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest 2008;134:831-834